AI-Designed vaccine takes on lung cancer in new trial
NCT ID NCT07285434
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a personalized vaccine called Microlyvaq™ for people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and quantum modeling to target their unique tumor mutations. It is given alongside standard chemotherapy and immunotherapy. The goal is to see if this approach can shrink tumors and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biogenea Pharmaceuticals Ltd
Thessaloniki, Macedonia, 54627, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a new drug combo outperform standard therapy for lung cancer?
- Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a novel drug combo outperform chemo in lung cancer?